Cargando…
Gut microbiota: A new therapeutic target for diabetic cardiomyopathy
Diabetic cardiomyopathy seriously affects quality of life and even threatens life safety of patients. The pathogenesis of diabetic cardiomyopathy is complex and multifactorial, and it is widely accepted that its mechanisms include oxidative stress, inflammation, insulin resistance, apoptosis, and au...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461091/ https://www.ncbi.nlm.nih.gov/pubmed/36091756 http://dx.doi.org/10.3389/fphar.2022.963672 |
_version_ | 1784786901704638464 |
---|---|
author | Yuan, Suxin Cai, Zhengyao Luan, Xingzhao Wang, Haibo Zhong, Yi Deng, Li Feng, Jian |
author_facet | Yuan, Suxin Cai, Zhengyao Luan, Xingzhao Wang, Haibo Zhong, Yi Deng, Li Feng, Jian |
author_sort | Yuan, Suxin |
collection | PubMed |
description | Diabetic cardiomyopathy seriously affects quality of life and even threatens life safety of patients. The pathogenesis of diabetic cardiomyopathy is complex and multifactorial, and it is widely accepted that its mechanisms include oxidative stress, inflammation, insulin resistance, apoptosis, and autophagy. Some studies have shown that gut microbiota plays an important role in cardiovascular diseases. Gut microbiota and its metabolites can affect the development of diabetic cardiomyopathy by regulating oxidative stress, inflammation, insulin resistance, apoptosis, and autophagy. Here, the mechanisms of gut microbiota and its metabolites resulting in diabetic cardiomyopathy are reviewed. Gut microbiota may be a new therapeutic target for diabetic cardiomyopathy. |
format | Online Article Text |
id | pubmed-9461091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94610912022-09-10 Gut microbiota: A new therapeutic target for diabetic cardiomyopathy Yuan, Suxin Cai, Zhengyao Luan, Xingzhao Wang, Haibo Zhong, Yi Deng, Li Feng, Jian Front Pharmacol Pharmacology Diabetic cardiomyopathy seriously affects quality of life and even threatens life safety of patients. The pathogenesis of diabetic cardiomyopathy is complex and multifactorial, and it is widely accepted that its mechanisms include oxidative stress, inflammation, insulin resistance, apoptosis, and autophagy. Some studies have shown that gut microbiota plays an important role in cardiovascular diseases. Gut microbiota and its metabolites can affect the development of diabetic cardiomyopathy by regulating oxidative stress, inflammation, insulin resistance, apoptosis, and autophagy. Here, the mechanisms of gut microbiota and its metabolites resulting in diabetic cardiomyopathy are reviewed. Gut microbiota may be a new therapeutic target for diabetic cardiomyopathy. Frontiers Media S.A. 2022-08-26 /pmc/articles/PMC9461091/ /pubmed/36091756 http://dx.doi.org/10.3389/fphar.2022.963672 Text en Copyright © 2022 Yuan, Cai, Luan, Wang, Zhong, Deng and Feng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Yuan, Suxin Cai, Zhengyao Luan, Xingzhao Wang, Haibo Zhong, Yi Deng, Li Feng, Jian Gut microbiota: A new therapeutic target for diabetic cardiomyopathy |
title | Gut microbiota: A new therapeutic target for diabetic cardiomyopathy |
title_full | Gut microbiota: A new therapeutic target for diabetic cardiomyopathy |
title_fullStr | Gut microbiota: A new therapeutic target for diabetic cardiomyopathy |
title_full_unstemmed | Gut microbiota: A new therapeutic target for diabetic cardiomyopathy |
title_short | Gut microbiota: A new therapeutic target for diabetic cardiomyopathy |
title_sort | gut microbiota: a new therapeutic target for diabetic cardiomyopathy |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461091/ https://www.ncbi.nlm.nih.gov/pubmed/36091756 http://dx.doi.org/10.3389/fphar.2022.963672 |
work_keys_str_mv | AT yuansuxin gutmicrobiotaanewtherapeutictargetfordiabeticcardiomyopathy AT caizhengyao gutmicrobiotaanewtherapeutictargetfordiabeticcardiomyopathy AT luanxingzhao gutmicrobiotaanewtherapeutictargetfordiabeticcardiomyopathy AT wanghaibo gutmicrobiotaanewtherapeutictargetfordiabeticcardiomyopathy AT zhongyi gutmicrobiotaanewtherapeutictargetfordiabeticcardiomyopathy AT dengli gutmicrobiotaanewtherapeutictargetfordiabeticcardiomyopathy AT fengjian gutmicrobiotaanewtherapeutictargetfordiabeticcardiomyopathy |